Capricor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Capricor and other ETFs, options, and stocks.

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. 

CEO
Linda Marbán
CEOLinda Marbán
Employees
231
Employees231
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1996
Founded1996
Employees
231
Employees231

CAPR Key Statistics

Market cap
222.39M
Market cap222.39M
Price-Earnings ratio
-1.81
Price-Earnings ratio-1.81
Dividend yield
Dividend yield
Average volume
8.68M
Average volume8.68M
High today
$4.66
High today$4.66
Low today
$3.80
Low today$3.80
Open price
$4.04
Open price$4.04
Volume
7.29M
Volume7.29M
52 Week high
$40.37
52 Week high$40.37
52 Week low
$2.96
52 Week low$2.96

Stock Snapshot

The current Capricor(CAPR) stock price is $3.86, with a market capitalization of 222.39M. The stock trades at a price-to-earnings (P/E) ratio of -1.81.

During the trading session on 2026-07-31, Capricor(CAPR) shares reached a daily high of $4.66 and a low of $3.80. At a current price of $3.86, the stock is +1.6% higher than the low and still -17.2% under the high.

Trading volume for Capricor(CAPR) stock has reached 7.29M, versus its average volume of 8.68M.

The stock's 52-week range extends from a low of $2.96 to a high of $40.37.

The stock's 52-week range extends from a low of $2.96 to a high of $40.37.

CAPR News

Investing.com 1d
Jones Trading downgrades Capricor Therapeutics stock rating after FDA panel vote - Investing.com

...

Jones Trading downgrades Capricor Therapeutics stock rating after FDA panel vote - Investing.com
TipRanks 1d
Capricor Faces FDA Panel Setback on Deramiocel Therapy

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 1d
Capricor: FDA committee voted evidence did not support Deramiocel effectiveness

Capricor Therapeutics (CAPR) announced that the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee voted that available...

Analyst ratings

100%

of 10 ratings
Buy
0%
Hold
100%
Sell
0%

More CAPR News

TipRanks 2d
Capricor Therapeutics announces publication of HOPE-3 data on deramiocel

Capricor Therapeutics (CAPR) announced that The Lancet has published results from the Company’s pivotal Phase 3 HOPE-3 clinical trial evaluating Deramiocel, its...

Simply Wall St 4d
Why Capricor Therapeutics Is Down 64.1% After FDA Flags Deramiocel Trial Concerns And Headquarters Bet

In July 2026, Capricor Therapeutics disclosed that FDA reviewers found no statistically significant benefit for its Duchenne muscular dystrophy cell therapy Der...

Why Capricor Therapeutics Is Down 64.1% After FDA Flags Deramiocel Trial Concerns And Headquarters Bet
Benzinga 4d
QUICK SPARK: Capricor Stock Dives — 'Complete Fraud' Says Pharma Bro Martin Shkreli

‘Pharma Bro’ Martin Shkreli is publicly accusing Capricor Therapeutics (NASDAQ:CAPR) of fraud and alleging legal action will be taken against its CEO and a cons...

QUICK SPARK: Capricor Stock Dives — 'Complete Fraud' Says Pharma Bro Martin Shkreli

People also own

Based on the portfolios of people who own CAPR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.